Schering extends use of Gadovist

Article

The European Union has approved the use of Schering's extracellular agent Gadovist 1.0 for use in MR angiography. Gadovist 1.0 previously had been cleared for contrast-enhanced MR of the brain and spine by EU members and other countries, including the

The European Union has approved the use of Schering's extracellular agent Gadovist 1.0 for use in MR angiography. Gadovist 1.0 previously had been cleared for contrast-enhanced MR of the brain and spine by EU members and other countries, including the U.S. It is the first extracellular contrast agent to receive EU approval for this indication.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Emerging Concepts in CT-Guided Treatment of Coronary Artery Disease
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Related Content
© 2025 MJH Life Sciences

All rights reserved.